0001511164-17-000512.txt : 20170815 0001511164-17-000512.hdr.sgml : 20170815 20170815124841 ACCESSION NUMBER: 0001511164-17-000512 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170815 DATE AS OF CHANGE: 20170815 EFFECTIVENESS DATE: 20170815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IASO BioMed, Inc. CENTRAL INDEX KEY: 0001662907 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473474169 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-215083 FILM NUMBER: 171033130 BUSINESS ADDRESS: STREET 1: 7315 E. PEAKVIEW AVE. CITY: CENTENNIAL STATE: CO ZIP: 80111 BUSINESS PHONE: (303) 796-8940 MAIL ADDRESS: STREET 1: 7315 E. PEAKVIEW AVE. CITY: CENTENNIAL STATE: CO ZIP: 80111 NT 10-Q 1 iasobiomedform12b2510q63017.htm NT 10-Q Converted by EDGARwiz



 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 12b-25

  

NOTIFICATION OF LATE FILING

 

SEC FILE NUMBER: 333-215083

CUSIP NUMBER: 45074X 103

Check One: 


o Form 10-K

o Form 20-F

o Form 11-K

x Form 10-Q

o Form 10-D

o Form N-SAR  

o Form N-CSR

 

 

For Period Ended: June 30, 2017

 

 

 

o Transition Report on Form 10-K

 

o Transition Report on Form 20-F

 

o Transition Report on Form 11-K

 

o Transition Report on Form 10-Q

 

o Transition Report on Form N-SAR

 

 

 

For the Transition Period Ended: ___________________

  

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

IASO BIOMED, INC

 

Full Name of Registrant

 

 

 

 

 

Former Name if Applicable

 

 

 

7315 East Peakview Avenue

 

Address of Principal Executive Office (Street and Number)

 

 

 

Centennial, Colorado 80111

 

City, State and Zip Code

 

 

 




1




PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

x

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

 

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR for Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-K, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

 

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

The Company was unable to compile the necessary financial information required to prepare a complete filing. Thus, the Company would be unable to file the periodic report in a timely manner without unreasonable effort or expense. The Company expects to file within the extension period.

 



2




PART IV — OTHER INFORMATION

 

(1)

Name and telephone number of person to contact in regard to this notification

 

Thomas B. Olson

 

720

 

389-0650

(Name)

 

(Area Code)

 

(Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes x No o

 

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes o No x

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

  



3




IASO BIOMED, INC.

 (Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: August 15, 2017

By:

/s/ Mr. Richard M. Schell

 

 

Name:

Mr. Richard M. Schell

 

 

Title:

Chief Executive Officer

 

  

 




4